Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective

Naga S. Samji, Rajanshu Verma, Sanjaya Satapathy

Research output: Contribution to journalReview article

Abstract

The incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10–15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbidity, and mortality, will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention, and a multitude of pharmaceutical companies are participating in active research trying to find a “cure”. Unfortunately, as of now, no targeted treatment exists to treat this condition, and therefore, emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.

Original languageEnglish (US)
Pages (from-to)497-505
Number of pages9
JournalJournal of Clinical and Experimental Hepatology
Volume9
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Liver Cirrhosis
Liver
Non-alcoholic Fatty Liver Disease
Life Style
Epidemiology
Obesity
Economics
Morbidity
Mortality
Incidence
Research
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Magnitude of Nonalcoholic Fatty Liver Disease : Western Perspective. / Samji, Naga S.; Verma, Rajanshu; Satapathy, Sanjaya.

In: Journal of Clinical and Experimental Hepatology, Vol. 9, No. 4, 01.07.2019, p. 497-505.

Research output: Contribution to journalReview article

@article{4be36168251042ce807217ab844f149c,
title = "Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective",
abstract = "The incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10–15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbidity, and mortality, will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention, and a multitude of pharmaceutical companies are participating in active research trying to find a “cure”. Unfortunately, as of now, no targeted treatment exists to treat this condition, and therefore, emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.",
author = "Samji, {Naga S.} and Rajanshu Verma and Sanjaya Satapathy",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.jceh.2019.05.001",
language = "English (US)",
volume = "9",
pages = "497--505",
journal = "Journal of Clinical and Experimental Hepatology",
issn = "0973-6883",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Magnitude of Nonalcoholic Fatty Liver Disease

T2 - Western Perspective

AU - Samji, Naga S.

AU - Verma, Rajanshu

AU - Satapathy, Sanjaya

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10–15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbidity, and mortality, will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention, and a multitude of pharmaceutical companies are participating in active research trying to find a “cure”. Unfortunately, as of now, no targeted treatment exists to treat this condition, and therefore, emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.

AB - The incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10–15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbidity, and mortality, will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention, and a multitude of pharmaceutical companies are participating in active research trying to find a “cure”. Unfortunately, as of now, no targeted treatment exists to treat this condition, and therefore, emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.

UR - http://www.scopus.com/inward/record.url?scp=85066778231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066778231&partnerID=8YFLogxK

U2 - 10.1016/j.jceh.2019.05.001

DO - 10.1016/j.jceh.2019.05.001

M3 - Review article

AN - SCOPUS:85066778231

VL - 9

SP - 497

EP - 505

JO - Journal of Clinical and Experimental Hepatology

JF - Journal of Clinical and Experimental Hepatology

SN - 0973-6883

IS - 4

ER -